Acetylcholine Receptor Modulating Antibody

This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.

Test Code
ACHRM

CPT Codes
83519

Specimen Container
No additive serum separator tube

Preferred Specimen
1 mL serum (0.3 mL minimum)

Transport Temperature
Refrigerated

Methodology
Radiobinding Assay

Reference Range

< 32% binding inhibition

Clinical Use
Myasthenia gravis (MG) is a neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. Modulating Antibody to AChR causes weakness by inhibiting or modulating binding to the receptors.

Performed By
Quest Diagnostics Nichols Institute